Tofacitinib is a small-molecule targeted synthetic DMARD. It was designed as a selective and specific inhibitor of pro-inflammatory receptor signalling (inhibition of janus kinases). Tofacitinib has been approved for use in the treatment of patients with moderate to severe active RA. An extended?release (XR) formulation has been designed to provide a once?daily (QD) dosing option to patients to achieve comparable pharmacokinetic (PK) parameters to the twice?daily immediate?release (IR) formulation.
In the treatment of adult patients with moderate to severe rheumatoid arthritis